Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
Protocol ID
RG_13-277 (rEECur)
Disease (Sub Disease)
Solid tumours (Ewings sarcoma)
Diagnosis Stage
Relapse/ refractory
Location
NSW, QLD, VIC, WA, SA, NZ
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
University of Birmingham
University of Birmingham
Collaborators
Australasian Sarcoma Study Group
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
John Hunter Children's Hospital
Monash Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Monash Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 2/3
Age Eligibility
4 years to 50 years
ANZCTR
ACTRN12618001825246
| Study Title | International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma |
|---|---|
| Protocol ID | RG_13-277 (rEECur) |
| Disease (Sub Disease) | Solid tumours (Ewings sarcoma) |
| Diagnosis Stage | Relapse/ refractory |
| Location | NSW / QLD / VIC / WA / SA / NZ |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ University of Birmingham |
| Collaborators | Australasian Sarcoma Study Group |
| Links | https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376265&isReview=true |
| Trial Status | Open |
| Trial Open Date | 03/04/2018 |
| Sites | The Children's Hospital at Westmead / John Hunter Children's Hospital / Monash Children's Hospital / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Women's & Children's Hospital / Christchurch Hospital / Starship Hospital |
| Study Type | Treatment |
| Phase | Phase 2/3 |
| Age Eligibility | 4 years to 50 years |
| ANZCTR | ACTRN12618001825246 |